These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27242186)

  • 1. Immunotherapy for gynecologic cancers.
    Liao JB
    Gynecol Oncol; 2016 Jul; 142(1):3-5. PubMed ID: 27242186
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cancer immunotherapy].
    Kjeldsen JW; Donia M; Svane IM
    Ugeskr Laeger; 2018 May; 180(21):. PubMed ID: 29804567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunities in immunotherapy of ovarian cancer.
    Coukos G; Tanyi J; Kandalaft LE
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Gynecologic Cancers: Are We There Yet?
    Pakish JB; Jazaeri AA
    Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [History of cancer therapy].
    Yamabe T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():22-7. PubMed ID: 15535200
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preface.
    Tainsky MA; Morris RT
    Cancer Metastasis Rev; 2015 Mar; 34(1):3. PubMed ID: 25648358
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy for gynaecological malignancies.
    Coukos G; Conejo-Garcia JR; Roden RB; Wu TC
    Expert Opin Biol Ther; 2005 Sep; 5(9):1193-210. PubMed ID: 16120050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human and medical aspects of treatment of recurrent gynecologic cancer].
    Revaz C
    Rev Med Suisse Romande; 1969 Jun; 89(6):679-95. PubMed ID: 5398848
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer.
    Eskander RN; Tewari KS
    Clin Ther; 2015 Jan; 37(1):20-38. PubMed ID: 25592089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cystomanometric studies following surgical and radiotherapeutic treatment of gynecologic tumors].
    Beckmann KH
    Zentralbl Gynakol; 1965 Dec; 87(49):1693-702. PubMed ID: 5869607
    [No Abstract]   [Full Text] [Related]  

  • 12. Melanoma vaccines: possible progress after years of frustration?
    Schmidt C
    J Natl Cancer Inst; 2009 Feb; 101(3):140-1. PubMed ID: 19176461
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy for gynecologic malignancies.
    Cohen CJ; Deppe G
    Prog Clin Biol Res; 1981; 70():371-4. PubMed ID: 7031696
    [No Abstract]   [Full Text] [Related]  

  • 14. Gearing up T-cell immunotherapy in cervical cancer.
    Chauhan SR; Bharadwaj M
    Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy.
    Yu WD; Sun G; Li J; Xu J; Wang X
    Cancer Lett; 2019 Jun; 452():66-70. PubMed ID: 30902563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
    Zheng Y; Yang Y; Wu S; Zhu Y; Tang X; Liu X
    Bioengineered; 2017 Jul; 8(4):367-373. PubMed ID: 27754760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Cervical Cancer.
    Mauricio D; Zeybek B; Tymon-Rosario J; Harold J; Santin AD
    Curr Oncol Rep; 2021 Apr; 23(6):61. PubMed ID: 33852056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
    Blair AB; Murphy A
    Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Jazaeri A; Coleman RL; Sood AK; Frumovitz MM; Soliman PT; Shafer A; Cutrera JJ; Klinger M; Sharafi SE; Johnson CAL; Villanueva VF; Hinchcliff EM; Dickens A; Cain KE; Anderson JE; Lu KH; Westin SN
    Gynecol Oncol; 2018 Nov; 151(2):374-380. PubMed ID: 30213435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer - 229 clinical cases].
    Nakamura K; Hanazawa S; Takeda T; Sumiyoshi R; Kobayashi S; Takeda H; Takeda T
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1295-7. PubMed ID: 25335722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.